摘要：Evaxion A/S凭借其AI-Immunology™平台荣获2026年英国盖伦奖“最佳数字健康解决方案”奖，这是该公司不到一年内第二次获得盖伦奖认可。该平台利用人工智能解码人类免疫系统，用于开发癌症和传染病的创新疫苗候选物。
COPENHAGEN, Denmark, June 12, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.丹麦哥本哈根，2026年6月12日——凭借其开创性的AI-Immunology™平台研发新型疫苗的临床阶段科技生物公司Evaxion A/S（纳斯达克股票代码：EVAX，以下简称“Evaxion”）荣获2026年法国-美国医学研究基金会英国奖“最佳数字健康解决方案（AI-Immunology™类）”。
The award is another strong external validation and recognition of the AI-Immunology™ platform, which harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.该奖项是对AI-Immunology™平台的又一重要外部认可与肯定，该平台借助人工智能的力量解码人类免疫系统，并为癌症和传染病研发新型候选疫苗。
The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History Museum in London. Evaxion and AI-Immunology™ was chosen by a committee of distinguished scientific leaders among 10 candidates.伊瓦克斯顿（Evaxion）首席执行官海伦·泰顿·马丁（Helen-Tayton Martin）在伦敦自然历史博物馆举行的英国盖伦奖（Prix Galien UK）颁奖典礼上领取了该奖项。在10名候选者中，伊瓦克斯顿公司及其AI-Immunology™技术由一众杰出的科学领袖组成的委员会选定获奖。
“We are honored to receive this distinction, which rewards the unique capabilities of AI-Immunology™ in effective vaccine target discovery, design and development. We are even more proud since this is the second recognition from the Galien Prix Foundation in less than a year. This kind of external validation is a great boost to our efforts to continuously improve AI-Immunology™ and bring forward safe and effective vaccine candidates in cancer and infectious disease,” says Helen Tayton-Martin.“我们很荣幸获得这一殊荣，它是对AI-Immunology™在高效疫苗靶点发现、设计与开发方面独特能力的肯定。更让我们自豪的是，这是加伦奖基金会在不到一年时间里给予我们的第二项认可。这种外部认可极大地鼓舞了我们持续优化AI-Immunology™、推进癌症和传染病领域安全有效疫苗候选物研发的努力，”海伦·泰顿-马丁说道。
In its evaluation, the jury focused on the innovation demonstrated throughout each candidate’s scientific development, clinical application, and utility. Further consideration was given to the insights it has advanced in biomedical science and the product’s tangible impact on human health.在评审中，评审团重点考察了每位候选人在科研发展、临床应用及实际效用方面所展现的创新能力。评审团还进一步考量了该成果在生物医学领域带来的新见解，以及其对人类健康产生的切实影响。
This is not the first time Evaxion has been recognized by the Galien Prix Foundation. In December 2025, we received the award for the Best Medical Technology / AI Advances in the Nordic and high-growth European and Middle Eastern countries.这并非伊瓦克斯昂公司首次获得盖伦奖基金会的认可。2025年12月，我们荣获北欧以及高增长的欧洲和中东国家最佳医疗技术/人工智能创新奖。
The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 62 products since inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 12 experts in the field, and includes a number of the UK’s leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.盖伦奖设立于1970年，1990年在英国启动，自创立以来已授予62款产品。该奖项每年由英国盖伦奖评审委员会评选产生，委员会由12名该领域专家组成，其中包括多位英国医疗保健领域的顶尖人物。这个资深专家团队秉持着一个坚定信念，即认可以研究为驱动的创新，是改善英国医疗保健事业以及全球人类健康状况的关键。